Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Antagonist for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a solid, orally active, non-selective beta-adrenergic receptor antagonist with a molecular weight of 309.40 g/mol and formula C₁₇H₂₇NO₄ (APExBIO). It functions both as a beta-adrenergic receptor blocker and as a substrate for organic anion transporting polypeptide 1A2 (OATP1A2), making it valuable for transporter and pharmacokinetic studies (Sun et al., 2025). Nadolol reduces heart rate and myocardial contractility, facilitating hypertension and angina pectoris research. The compound is stable at -20°C, but solutions should be used promptly to maintain efficacy. Shipping is optimized for compound stability, using Blue Ice or Dry Ice depending on molecular class (APExBIO).

Biological Rationale

Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor antagonist, meaning it blocks both β₁ and β₂ adrenergic receptors. This blockade reduces sympathetic stimulation of the heart and vascular system. Such antagonism is crucial in cardiovascular research for generating reproducible models of hypertension, angina pectoris, and vascular headaches. Beta-blockers are frontline agents for studying adrenergic signaling and cardiac workload modulation. Additionally, Nadolol’s role as an OATP1A2 substrate enables researchers to probe transporter-mediated drug interactions and disposition, which is central to translational pharmacokinetics (Sun et al., 2025).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol competitively inhibits beta-adrenergic receptors on cardiac and smooth muscle cells. By blocking β₁ receptors, Nadolol attenuates the effects of endogenous catecholamines (epinephrine, norepinephrine) on heart rate, contractility, and conduction velocity. Inhibition of β₂ receptors reduces vasodilation and bronchodilation. The net effect is a decrease in cardiac output and blood pressure, with diminished myocardial oxygen demand (APExBIO). Nadolol does not exhibit intrinsic sympathomimetic or membrane-stabilizing activity, ensuring a clean pharmacological profile. As a substrate of OATP1A2, Nadolol’s cellular uptake and tissue distribution are also influenced by transporter expression levels, especially in hepatic and vascular tissues (Sun et al., 2025).

Evidence & Benchmarks

• Nadolol (SQ-11725) demonstrated high oral bioavailability and predictable pharmacokinetics in preclinical rodent models (Sun et al., 2025, DOI).
• The compound’s beta-blocking activity has been validated in isolated tissue and whole-animal cardiovascular assays (APExBIO, product page).
• In cell-based transporter assays, Nadolol’s OATP1A2 substrate characteristics enable interrogation of transporter-mediated pharmacokinetics (Sun et al., 2025, DOI).
• Benchmarked protocols for hypertension and angina pectoris studies using Nadolol are described in current cardiovascular research guidelines (see comparative applications).
• Storage at -20°C preserves compound integrity for at least 12 months, with solutions recommended for immediate use to maximize efficacy (APExBIO, product page).

Applications, Limits & Misconceptions

Nadolol (SQ-11725) is widely applied in:

• Hypertension research: Establishes controlled models of beta-adrenergic blockade (see scenario-driven optimization; this article provides updated transporter insights compared to that resource).
• Angina pectoris studies: Reduces myocardial oxygen consumption for ischemia modeling.
• Vascular headache models: Provides robust adrenergic modulation in preclinical testing.
• Pharmacokinetic transporter studies: Enables investigation of OATP1A2-mediated drug disposition (DOI).

Compared to translational frameworks, this article details specific storage and workflow parameters based on the latest product and literature evidence.

Common Pitfalls or Misconceptions

• Not for human or diagnostic use: Nadolol (SQ-11725) is strictly for scientific research; clinical or diagnostic applications are not supported (APExBIO).
• Solution stability: Prepared solutions should not be stored long-term; efficacy declines with prolonged storage even at -20°C.
• Selectivity: Nadolol is non-selective; it blocks both β₁ and β₂ receptors, which may not be suitable for studies requiring subtype-specific inhibition.
• Transporter interactions: OATP1A2 substrate status may confound pharmacokinetic studies with co-administered transporter substrates or inhibitors.
• Extrapolation limits: Rodent pharmacokinetics may not fully predict human disposition due to interspecies transporter expression differences (DOI).

Workflow Integration & Parameters

Nadolol (SQ-11725) (SKU BA5097) is supplied as a solid and should be stored at -20°C in a desiccated environment. For solution preparations, use freshly made aliquots and avoid repeated freeze-thaw cycles. Shipping conditions are optimized by APExBIO: Blue Ice for small molecules, Dry Ice for nucleotides. For cardiovascular assays, dosing should be aligned with published preclinical protocols. The compound’s physicochemical profile supports integration into in vivo, ex vivo, and cell-based models. For transporter studies, co-incubation with known OATP1A2 modulators is advised to delineate uptake mechanisms (DOI).

Compared to protocol guides, this article emphasizes rapid-use solutions and OATP1A2-specific considerations.

Conclusion & Outlook

Nadolol (SQ-11725) is a validated non-selective beta-adrenergic antagonist and OATP1A2 substrate, suitable for a wide spectrum of cardiovascular and pharmacokinetic research applications. Its robust performance in preclinical assays, combined with well-characterized handling and storage parameters, make it a preferred tool for mechanistic and translational studies. Ongoing research into transporter-mediated pharmacokinetics and beta-adrenergic signaling will continue to refine Nadolol’s experimental utility (Sun et al., 2025).